The results of two clinical trials support the use of Ofev for patients with idiopathic pulmonary fibrosis.
The trials included IPF patients at different disease stages, and revealed that Ofev treatment is effective across groups with different disease severity.
The results were presented at this year’s annual meeting of the American College of Chest Physicians (CHEST), that took place through Wednesday, Oct. 26, in Los Angeles.
INPULSIS-1 (NCT01335464) and INPULSIS-2 (NCT01335477) analyzed the effectiveness of Ofev in IPF progression. In each clinical trial, participants were divided in sub-categories based primarily on three parameters using the GAP composite index (gender, age, and physiology) to predict prognosis in IPF patients.
In the presentation “Nintedanib Reduces Disease Progression in Patients With Idiopathic Pulmonary Fibrosis Irrespective of GAP Stage at Baseline in the INPULSIS Trials,” researchers recounted the investigation into whether Ofev could reduce the risk of disease progression compared to placebo in patients with different GAP stages.
The study utilized 500 participants at GAP 1, and 560 participants at GAP 2 or Gap 3. Within the GAP 1 group, 304 patients were given Ofev, while in the GAP 2-3 group, 334 patients received the therapy. The remaining participants in both groups received placebo.